TABLE 2.
Review of case series of pediatric patients with IBD treated with tofacitinib
| Publication, number and age of patients | Patients | Duration of tofacitinib | Clinical remission | Colectomy | Response | Therapy at the end of follow-up |
|---|---|---|---|---|---|---|
| Dolinger et al (33) 2019 | IBD-U1 | 5 wk | No | No | Primary nonresponse | UST |
| IBD-U2 | 12.9 wk | Yes | No | Clinical remission off systemic corticosteroids | Combination TOFA/VDZ, rectal steroid enemas | |
| UC1 | 9 wk | Yes | No | Clinical response, no remission, slowly tapering steroids | Combination TOFA/VDZ | |
| UC2 | 11.7 wk | Yes | No | Steroid-free clinical remission | Combination TOFA/VDZ | |
| UC3 | 40.4 wk | Yes | No | Clinical remission off systemic steroids | TOFA oral budesonide | |
| UC4 | 10.3 wk | No | No | No remission achieved. Variable disease course | TOFA | |
| UC5 | 9 wk | Yes | No | Steroid-free clinical remission | TOFA | |
| Twelve pediatric patients with biologic-refractory IBD | CD1 | 8.4 wk | No | No | Primary nonresponse | UST |
| Diverting ileostomy | ||||||
| Median age 16 y (14–17 y) | CD2 | 8 wk | No | No | Primary nonresponse | |
| CD3 | 58.8 wk | No | No | No remission achieved. Variable disease course | ||
| CD4 | 10.7 wk | Yes | No | Steroid-free clinical remission | Combination TOFA/VDZ | |
| CD5 | 5 wk | No | No | Primary nonresponse | Diverting ileostomy | |
| Moore et al (35) 2021 | UC (n = 14) | At week 6 | n = 4/21 | n = 4 | Clinical response n = 10/21, 8 on steroids | |
| Twenty-one pediatric patients and younger adult with biologic-refractory IBD | IBD-U (n = 4) | At week 12 (17 patients completed induction) | n = 7/21 | Clinical response n = 7/21, 5 on steroids | ||
| Median age 18.4 y (15.1–19.1 y) | CD (n = 3) | At week 24 (15 patients on TOFA) | n = 7/17 | Clinical response n = 12/17, 1 on steroids | ||
| At week 52 (10 patients on TOFA) | n = 7/17 with steroid-free clinical remission | n = 2 | Clinical response n = 7/17, 0 on steroids |
CD = Crohn disease; IBD = inflammatory bowel disease, IBD-U = inflammatory bowel disease unclassified; TOFA = tofacitinib; UC = ulcerative colitis; UST = ustekinumab; VDZ = vedolizumab.